[ Syndrome myélodysplasique secondaire à une greffe de cellules souches hématopoïétiques périphériques autologues dans le cadre d’un myélome multiple ]
Volume 66, Issue 2, May 2023, Pages 321–324
Naoual Hasnaoui1, Kawtar ZINE FILALI2, and Taieb AGOURRAM3
1 Department of Clinical Hematology, Hassan II Oncology Centre, Oujda, Morocco
2 Service d’Hématologie Clinique et de Greffe, Clinique Ibn Rochd, Rabat, Morocco
3 Service d’Hématologie biologique et Immunologie, laboratoire Professeur Alaoui, Rabat, Morocco
Original language: French
Copyright © 2023 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction: Peripheral hematopoietic stem cell transplantation followed by maintenance Lenalidomide remains the standard of care for patients with multiple myeloma. The development of myelodysplastic syndrome is a serious complication that increases patient morbidity and mortality. Observation: We report the case of a young patient who developed a secondary myelodysplastic syndrome one year after autologous stem cell transplantation for multiple myeloma. Conclusion: With the improved survival of patients with multiple myeloma, early diagnosis of complications secondary to autologous hematopoietic stem cell transplantation, including myelodysplastic syndrome, should be part of the long-term care of these patients.
Author Keywords: Therapy-related myelodysplastic syndrome, multiple myeloma, autologous transplantation.
Volume 66, Issue 2, May 2023, Pages 321–324
Naoual Hasnaoui1, Kawtar ZINE FILALI2, and Taieb AGOURRAM3
1 Department of Clinical Hematology, Hassan II Oncology Centre, Oujda, Morocco
2 Service d’Hématologie Clinique et de Greffe, Clinique Ibn Rochd, Rabat, Morocco
3 Service d’Hématologie biologique et Immunologie, laboratoire Professeur Alaoui, Rabat, Morocco
Original language: French
Copyright © 2023 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction: Peripheral hematopoietic stem cell transplantation followed by maintenance Lenalidomide remains the standard of care for patients with multiple myeloma. The development of myelodysplastic syndrome is a serious complication that increases patient morbidity and mortality. Observation: We report the case of a young patient who developed a secondary myelodysplastic syndrome one year after autologous stem cell transplantation for multiple myeloma. Conclusion: With the improved survival of patients with multiple myeloma, early diagnosis of complications secondary to autologous hematopoietic stem cell transplantation, including myelodysplastic syndrome, should be part of the long-term care of these patients.
Author Keywords: Therapy-related myelodysplastic syndrome, multiple myeloma, autologous transplantation.
Abstract: (french)
Introduction: La greffe de cellules souches hématopoïétiques périphériques suivie d’un traitement d’entretien par du Lenalidomide, reste le traitement de base des patients atteints de myélome multiple. Le développement d’un syndrome myélodysplasique est une complication redoutable, augmentant ainsi la morbidité et la mortalité des patients. Observation: Nous rapportons le cas d’un jeune patient qui a développer un syndrome myélodysplasique à un an en post greffe pour un myélome multiple. Conclusion: Avec l’amélioration de la survie des patients atteints de myélome multiple, le diagnostique précoce des complications secondaires à l’autogreffe de cellules souches hématopoïétiques notamment le syndrome myélodysplasique devrait faire partie de la surveillance à long terme de ces patients.
Author Keywords: Syndrome myélodysplasique secondaire, autogreffe de cellules souches, myélome multiple.
How to Cite this Article
Naoual Hasnaoui, Kawtar ZINE FILALI, and Taieb AGOURRAM, “Secondary myelodysplastic syndrome after autologous peripheral hematopoietic stem cell transplantation in multiple myeloma,” International Journal of Innovation and Scientific Research, vol. 66, no. 2, pp. 321–324, May 2023.
